Mentions
Extended reach
Total likes
Video views
AI synopsis
Participants widely praise the article's significance, referencing its status as the most downloaded in 2022 and noting the detailed review on targeting KRAS and immune inhibition, fostering interest and recognition of its impact. The tone is generally positive and engaged, with mentions of related interviews and developments, although some comments are more about learning from the content rather than critical analysis.
Most discussions express favorable views, highlighting the significance of the research and its potential impact, indicating general agreement with the publication's importance.
The strong focus on KRAS, immunotherapy, and biomarkers shows high interest among participants, with multiple mentions of ongoing developments and clinical relevance.
Comments reflect some in-depth engagement, such as discussions about KRAS inhibitors and the potential for future strategies, but lack extensive critique or detailed analysis.
The discussions suggest the article is considered influential, especially as it being the top downloaded publication of 2022 and sparking multiple interviews and online discussions.
Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice review by Kato, Fujiwara, and Hong! https://t.co/1NzXUnnFuu
New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35mF5cYMAB Read: https://t.co/coCAlZqOww #Biomarker @R_Okamura_MD @jacobadashek @Dr_R_Kurzrock @mirella_nardo @OncologyNetwork
Now available online! It was really fun to learn how KRAS inhibitors have been developed and work with Dr. Kato and Dr. Hong (@DavidHongMD). Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology https://t.co/We7ll1i6Bn
What a pleasure to conduct this @JIPOEditors Interview: Dr Razelle Kurzrock on PD-1 for predicting response to anti-PF1/PD-L1. https://t.co/7uxyLsNhKV via @YouTube
#JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35mF5cYMAB Read: https://t.co/coCAlZqOww #Biomarker @R_Okamura_MD @jacobadashek @Dr_R_Kurzrock @mirella_nardo @OncologyNetwork
#1 most downloaded #JIPO article of 2022: "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Kato et al. https://t.co/qDi8i1ufHm #KRAS #immunotherapy #ICIs #review https://t.co/tkFueBhYvz
Dr David Hong discusses his publication on targeting KRAS, focusing on the crossroads of signaling pathways and immune inhibition. The review covers RAS mutations in cancers, recent advances with G12C inhibitors, and…
RT @JIPOEditors: #1 most downloaded #JIPO article of 2022: "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Kato et al.…
RT @JIPOEditors: #1 most downloaded #JIPO article of 2022: "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Kato et al.…
#1 most downloaded #JIPO article of 2022: "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Kato et al. https://t.co/qDi8i1ufHm #KRAS #immunotherapy #ICIs #review https://t.co/tkFueBhYvz
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
#JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35mF5cYMAB Read: https://t.co/coCAlZqOww #Biomarker @R_Okamura_MD @jacobadashek @Dr_R_Kurzrock @mirella_nardo @OncologyNetwork
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
RT @JIPOEditors: #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35m…
#JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35mF5cZkq9 Read: https://t.co/coCAlZrmm4 #Biomarker @R_Okamura_MD @jacobadashek @Dr_R_Kurzrock @mirella_nardo @OncologyNetwork
RT @JIPOEditors: New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co…
RT @JIPOEditors: New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co…
RT @JIPOEditors: New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co…
RT @JIPOEditors: New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co…
RT @JIPOEditors: New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co…
New #JIPO interview: Dr. Razelle Kurzrock discusses using PD-1 to predict response to #immunotherapy Listen: https://t.co/35mF5cYMAB Read: https://t.co/coCAlZqOww #Biomarker @R_Okamura_MD @jacobadashek @Dr_R_Kurzrock @mirella_nardo @OncologyNetwork
RT @mirella_nardo: What a pleasure to conduct this @JIPOEditors Interview: Dr Razelle Kurzrock on PD-1 for predicting response to anti-PF1/…
What a pleasure to conduct this @JIPOEditors Interview: Dr Razelle Kurzrock on PD-1 for predicting response to anti-PF1/PD-L1. https://t.co/7uxyLsNhKV via @YouTube
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
RT @Dr_R_Kurzrock: Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice…
Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology. Nice review by Kato, Fujiwara, and Hong! https://t.co/1NzXUnnFuu
New interview about targeting KRAS from JIPO! @JIPOEditors @jibranahmed1 https://t.co/nUP8H3kaNx
RT @JIPOEditors: Watch and read "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Shumei Kato, Yu Fujiwara, and David S. H…
RT @JIPOEditors: Watch and read "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Shumei Kato, Yu Fujiwara, and David S. H…
RT @JIPOEditors: Watch and read "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Shumei Kato, Yu Fujiwara, and David S. H…
RT @JIPOEditors: Watch and read "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Shumei Kato, Yu Fujiwara, and David S. H…
Watch and read "Targeting KRAS: Crossroads of Signaling and Immune Inhibition" by Shumei Kato, Yu Fujiwara, and David S. Hong. Read: https://t.co/qDi8i1ufHm Watch: https://t.co/LntuYyzdPR #KRASmutation #immunecheckpointinhibitor @waraonc23 @DavidHongMD @ANaingMD
New article: Targeting KRAS: Crossroads of Signaling and Immune Inhibition https://t.co/gLzoxLedYv #pancreaticcancer #oncology https://t.co/AyeMNvXsXl
RT @waraonc23: Now available online! It was really fun to learn how KRAS inhibitors have been developed and work with Dr. Kato and Dr. Hong…
RT @waraonc23: Now available online! It was really fun to learn how KRAS inhibitors have been developed and work with Dr. Kato and Dr. Hong…
RT @waraonc23: Now available online! It was really fun to learn how KRAS inhibitors have been developed and work with Dr. Kato and Dr. Hong…
Now available online! It was really fun to learn how KRAS inhibitors have been developed and work with Dr. Kato and Dr. Hong (@DavidHongMD). Targeting KRAS: Crossroads of Signaling and Immune Inhibition | Journal of Immunotherapy and Precision Oncology https://t.co/We7ll1i6Bn
RM
YM
JE
CM
C
GB
HT
GS
KS
JP
T
I
DM
PO
CF
AO